Literature DB >> 7841080

An approach to radical excision of craniopharyngioma by the temporal route.

L Symon1.   

Abstract

Attempts at radical excision of craniopharyngioma has been made increasingly possible by the advent of neuroradiological imaging and the use of microscopic technique. Between 1977 and 1993, 62 patients of The National Hospital for Neurology and Neurosurgery, London, have undergone surgical excision of craniopharyngioma by the temporal route, with a small anterior temporal resection. Surgical mortality was 4%. Forty-eight patients (76%) remain well on average follow-up of 34 months. Twelve percent had major complications (hypothalamic damage, subdural haematoma, scalp collections requiring shunt drainage). There were four recurrences in patients where the initial operations were considered as complete microscopic excision. Maximal control of tumour recurrence by removal of all tumour accessible and visible to the surgical microscope is best achieved by radical excision at the first operation.

Entities:  

Mesh:

Year:  1994        PMID: 7841080     DOI: 10.1159/000120864

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  3 in total

1.  Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma.

Authors:  S Cavalheiro; P A Dastoli; N S Silva; S Toledo; H Lederman; M C da Silva
Journal:  Childs Nerv Syst       Date:  2005-06-14       Impact factor: 1.475

Review 2.  Craniopharyngioma adherence: a reappraisal of the evidence.

Authors:  Ruth Prieto; José María Pascual; Verena Hofecker; Eduard Winter; Inés Castro-Dufourny; Rodrigo Carrasco; Laura Barrios
Journal:  Neurosurg Rev       Date:  2018-07-24       Impact factor: 3.042

3.  Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Shanna Fang; Aaron J Clark; Derrick Aranda; Igor J Barani; Andrew T Parsa
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.